Somatostatin-receptor scintigraphy for staging and follow-up of patients with extraintestinal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT)-type

What Was Tested

This clinical trial paper looks at Octreotide and Somatostatin.

Due to previous results indicating that somatostatin receptor (SSTR)-expression distinguishes between gastric and extragastric MALT-type lymphoma, the researchers have initiated a study to evaluate the role of SSTR-scintigraphy for staging and follow-up of patients with extragastric manifestations of MALT-type lymphoma.

Why It Was Studied

The majority of lymphomas of the mucosa-associated lymphoid tissue (MALT)-type arise in the stomach, but extragastric locations are also frequently encountered.

All patients had histologically verified MALT-type lymphoma: 2 patients had lymphoma presenting in the lung, 9 in the ocular adnexa, 7 had lymphomas in the parotid, 2 patients had disease located in the breast, 3 patients had lymph-node relapse following MALT-type lymphoma of the parotid, the lacrimal gland and the thyroid, and 1 had primary MALT-lymphoma of the liver.

Who Took Part

The abstract describes 30 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

What Was Measured

All patients had histologically verified MALT-type lymphoma: 2 patients had lymphoma presenting in the lung, 9 in the ocular adnexa, 7 had lymphomas in the parotid, 2 patients had disease located in the breast, 3 patients had lymph-node relapse following MALT-type lymphoma of the parotid, the lacrimal gland and the thyroid, and 1 had primary MALT-lymphoma of the liver.

No positive scans could be obtained in patients with dissemination following gastric lymphoma, while all patients with primary extragastric lymphoma had positive scans at the site of histologically documented involvement before initiation of therapy.

Topics PubMed links to this paper include Lymph Nodes, Lymphatic Metastasis, Lymphoma, B-Cell, Marginal Zone, Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasm Staging and Octreotide.

What This Means in Plain Language

This is a clinical trial of Octreotide and Somatostatin in 30 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2001 (British journal of cancer), a journal based in England.

More context: the Octreotide compound page and the Somatostatin compound page, all human trials.